新斯的明治疗重症急性胰腺炎患者胃肠动力障碍的疗效与安全性:随机对照试验研究方案
本试验为随机、安慰剂对照、双盲、单中心试验,拟纳入最多56例重症急性胰腺炎患者,随机接受新斯的明甲硫酸盐注射液0.5 mg/1 ml每日两次或1 ml生理盐水每日两次,评估排便时间、死亡率与器官衰竭、肠鸣音、肠内营养启动时间、腹内压及ICU和住院时长。
要点
- 新斯的明可增加胃肠动力,已用于术后胃肠动力障碍,但在急性胰腺炎中研究有限。
- 试验拟纳入最多56例重症急性胰腺炎患者,随机接受新斯的明0.5 mg/1 ml每日两次或生理盐水1 ml每日两次。
- 主要评估指标包括排便时间、死亡率与器官衰竭、肠鸣音、肠内营养启动时间、腹内压及ICU和住院时长。
核心结论
- 本试验旨在验证新斯的明能否改善重症急性胰腺炎患者的胃肠动力。
- 研究结果将为新斯的明治疗重症急性胰腺炎胃肠动力障碍提供数据支持。
研究设计与样本
- 随机、安慰剂对照、双盲、单中心试验。
- 拟纳入最多56例重症急性胰腺炎患者。
- 随机接受新斯的明甲硫酸盐注射液0.5 mg/1 ml每日两次或1 ml生理盐水每日两次。
主要发现
- 评估排便时间(目标1)。
- 评估死亡率与器官衰竭(目标2)。
- 评估肠鸣音、肠内营养启动时间及腹内压(目标3)。
- 评估ICU和住院时长(目标4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute pancreatitis is a serious threat to human health and gastrointestinal dysmotility is a common complication for acute pancreatitis patients, resulting in delayed feeding, oral feeding intolerance, paralytic ileus, and abdominal compartment syndrome. Currently, there are limited treatment for this complication. Neostigmine is known to increase gastrointestinal motility and has been used to treat gastrointestinal dysmotility after surgery. However, research in treating acute pancreatitis with neostigmine is currently limited. METHODS: This trial is a randomized, placebo-controlled, double-blinded, mono-centric trial that will test the hypothesis that neostigmine can improve gastrointestinal motility in patients with severe acute pancreatitis. Up to 56 patients will be randomized in this study receiving 0.5 mg/1 ml of neostigmine methylsulfate injection twice per day or 1 ml of saline injection twice per day. Defection time (aim 1), mortality and organ failure (aim 2), borborygmus, starting of enteral nutrition and intra-abdominal pressure (aim 3), and length of ICU and hospital stay (aim 4) will be assessed. DISCUSSION: Findings from this study will provide data supporting the usage of neostigmine for treating severe acute pancreatitis patients with gastrointestinal dysmotility. TRIAL REGISTRATION: This study is registered on chictr.org.cn with the identifier as ChiCTR2200058305. Registered on April 5, 2022.
引用
- Sun H, Sheng Y, Du T, et al. Efficacy and safety of neostigmine on treating gastrointestinal dysmotility in severe acute pancreatitis patients: study protocol for a randomized controlled trial. Trials. 2023. PMID: 36747275. doi:10.1186/s13063-023-07086-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。